Cardiac Biotech Solutions (CBSC) Stock Overview
Through its subsidiaries, provides ambulatory non-invasive cardiac monitoring products and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CBSC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cardiac Biotech Solutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.04 |
| 52 Week High | US$0.077 |
| 52 Week Low | US$0.016 |
| Beta | 0 |
| 1 Month Change | -32.20% |
| 3 Month Change | 60.06% |
| 1 Year Change | 21.21% |
| 3 Year Change | -75.76% |
| 5 Year Change | -96.36% |
| Change since IPO | -96.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBSC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -1.7% |
| 1Y | 21.2% | 17.1% | 13.8% |
Return vs Industry: CBSC exceeded the US Pharmaceuticals industry which returned 16.9% over the past year.
Return vs Market: CBSC exceeded the US Market which returned 13.1% over the past year.
Price Volatility
| CBSC volatility | |
|---|---|
| CBSC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine CBSC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Chip Martin | cardiacbiotech.com |
Cardiac Biotech Solutions Inc., through its subsidiaries, provides ambulatory non-invasive cardiac monitoring products and services in the United States and internationally. It offers My-Cardia devices, interactive cloud-based acquisition software, and smartphone apps for patients at risk of abnormal heart rhythms. The company was formerly known as CB Scientific, Inc. and changed its name to Cardiac Biotech Solutions Inc. in May 2025.
Cardiac Biotech Solutions Inc. Fundamentals Summary
| CBSC fundamental statistics | |
|---|---|
| Market cap | US$6.62m |
| Earnings (TTM) | -US$640.55k |
| Revenue (TTM) | US$50.37k |
Is CBSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBSC income statement (TTM) | |
|---|---|
| Revenue | US$50.37k |
| Cost of Revenue | US$23.00k |
| Gross Profit | US$27.37k |
| Other Expenses | US$667.92k |
| Earnings | -US$640.55k |
Last Reported Earnings
Dec 31, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CBSC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/23 19:44 |
| End of Day Share Price | 2026/03/23 00:00 |
| Earnings | 2018/12/31 |
| Annual Earnings | 2018/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cardiac Biotech Solutions Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.